An oral thin film for inhibiting the progression of macular degeneration, having as active ingredients a zinc compound, lutein, or zeaxanthin, or a combination thereof, contained in an ingestible oral thin film. The oral thin film is placed in the mouth of a user and allowed to dissolve therein. The zinc compound, lutein, or zeaxanthin, or a combination thereof, is ingested in a liquid form by the user after the oral thin film dissolves. The active ingredients are delivered to the gastrointestinal tract of the user where they are absorbed into the systemic circulation. The zinc compound may be microencapsulated to prevent the metallic taste of the zinc compound.
